Skin Cancer Risk Linked to Xeljanz, Jakafi, Other JAK Inhibitors: Study
Xeljanz, Jakafi and other JAK inhibitors were linked to an increased risk of melanoma, squamous cell carcinoma and Merkel cell carcinoma
Xeljanz, Jakafi and other JAK inhibitors were linked to an increased risk of melanoma, squamous cell carcinoma and Merkel cell carcinoma
skin cancer, particularly melanoma, is a significant cause of death for immunosuppressed solid organ transplant recipients, researchers warn.
Lawsuit alleges manufacturers of firefighting foam failed to disclose risk that PFAS may infiltrated human blood, leading to the diagnosis of skin cancer
Study comes amid closer scrutiny of sunscreen product ingredients due to revelations that many contain the cancer-causing chemical benzene.